Morgan Stanley Chemomab Therapeutics Ltd. Call Options Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CMMB
# of Institutions
14Shares Held
4.22MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA941KShares$2.89 Million0.04% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3738KShares$2.27 Million0.24% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3578KShares$1.78 Million0.12% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$654,0690.08% of portfolio
-
Rhumbline Advisers Boston, MA39.9KShares$122,4160.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $35.1M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...